Announcements Trials
Browse Landscape

Phase

Phase 2 18Phase 1 6Phase 3 3Phase 4 2Phase 2/3 2Phase 1/2 2Phase NA 1

Status

Unknown 1Recruiting 1

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Myeloid 2

Conditions

Myelodysplastic Syndromes 19Leukemia, Myeloid, Acute 17Precursor Cell Lymphoblastic Leukemia-Lymphoma 13Leukemia, Myelogenous, Chronic, BCR-ABL Positive 12Leukemia 8Hematologic Neoplasms 6Anemia, Refractory, with Excess of Blasts 6Lymphoma 5Primary Myelofibrosis 4Neoplasms 4Multiple Myeloma 4Mastocytosis 4Leukemia, Myelomonocytic, Chronic 4Leukemia, Myeloid, Chronic-Phase 4Leukemia, Myeloid, Accelerated Phase 4Leukemia, Biphenotypic, Acute 4Graft vs Host Disease 4Lymphoma, Non-Hodgkin 3Thyroid Carcinoma, Anaplastic 2Thyroid Cancer, Papillary 2Ovarian Neoplasms 2Neoplasms by Site 2Neoplasms by Histologic Type 2Myeloproliferative Disorders 2Melanoma 2Mastocytosis, Systemic 2Lymphohistiocytosis, Hemophagocytic 2Leukemia, Myelomonocytic, Acute 2Laryngeal Neoplasms 2Glioma 2

Interventions

Cladribine 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 2/3 × Mastocytosis, Systemic × Myeloid × Clear all
NCT04910685 2026-05-22

(HARBOR) Study to Evaluate Efficacy and Safety of BLU-263 Versus Placebo in Patients With Indolent Systemic Mastocytosis

Blueprint Medicines Corporation

Phase 2/3 Recruiting
534 enrolled
Myeloid

Mastocytosis, Systemic

NCT01602939 2016-08-29

Cladribine Plus Pegylated Interpheron Alfa-2a in Systemic Mastocytosis

Hospital Virgen de la Salud

Phase 2/3 Unknown
10 enrolled
Myeloid

Mast Cell Activation Disorders, Mastocytosis, Mastocytosis, Systemic

Data powered by HemOnc (CC BY 4.0) Colophon âš¡